Treatment of invasive aspergillosis in children with hematologic malignancies

被引:4
作者
Walid Abuhammour
Rashed A. Hasan
机构
[1] Michigan State University,Pediatric Infectious Disease, Hurley Medical Center
[2] Hurley Medical Center,One Hurley Plaza
[3] Hurley Medical Center,undefined
关键词
Invasive aspergillosis; Children; Hematologic malignancies;
D O I
10.1007/BF02730724
中图分类号
学科分类号
摘要
The respiratory tract is the most common organ involved with Aspergillosis in children with hematologic malignancies. AlsoAspergillus species tend to invade blood vessels resulting in systemic dissemination to multiple organs. Early diagnosis and treatment are pivotal to the patient’s outcome. A high index of suspicion should be maintained in children who have profound neutropenia and present with prolonged fever that is unresponsive to systemic antibiotics. Several diagnostic modalities should be used simultaneously in order to confirm the diagnosis in an expedited manner. Combination and sequential antifungal therapy have been shown to be of added benefit. Surgical intervention is associated with a high mortality rate, but may be indicated in children with a localized disease. In this article the authors review the epidemiology, microbiology, pathology, and clinical manifestations of invasive aspergillosis in children with hematologic malignancies. Current diagnostic approach, medical, and surgical treatment options are discussed.
引用
收藏
页码:837 / 843
页数:6
相关论文
共 104 条
[21]  
Novelli V(2003) associated diseases Clin Infect Dis 37 S188-224
[22]  
Costoli V(1998)Combination and Sequential Antifungal Therapy for Invasive Aspergillosis: Review of Published Adv Pharmacol 44 343-500
[23]  
Gerson SI(1998) and Clin Infect Dis 26 1383-1390
[24]  
Talbot GH(1997) Interactions and 6281 Clinical Cases from 1966 to 2001 Clin Infect Dis. 24 635-641
[25]  
Lusk E(1994)Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development Am J Med 97 135-144
[26]  
Gefter WB(1998)Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 patients Antimicrob Agents Chemother 42 899-902
[27]  
Albelda SM(2000)Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis Clin Infect Dis 31 1155-1163
[28]  
Talbot GH(1998)NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis Pediatr Infect Dis 17 146-148
[29]  
Taccone A(2002)Comparison of Fungisone, Amphotec, Ambisome, arid abelcet for treatment of systemic murine cryptococcosis N Eng J Med 347 408-415
[30]  
Occhi M(2002)A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Pediatr Infect Dis J 21 240-248